[go: up one dir, main page]

RU2019126574A3 - - Google Patents

Download PDF

Info

Publication number
RU2019126574A3
RU2019126574A3 RU2019126574A RU2019126574A RU2019126574A3 RU 2019126574 A3 RU2019126574 A3 RU 2019126574A3 RU 2019126574 A RU2019126574 A RU 2019126574A RU 2019126574 A RU2019126574 A RU 2019126574A RU 2019126574 A3 RU2019126574 A3 RU 2019126574A3
Authority
RU
Russia
Application number
RU2019126574A
Other versions
RU2019126574A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019126574A publication Critical patent/RU2019126574A/ru
Publication of RU2019126574A3 publication Critical patent/RU2019126574A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
RU2019126574A 2017-02-10 2018-02-09 Потенциаторы рецепторов ampa RU2019126574A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1702221.1A GB201702221D0 (en) 2017-02-10 2017-02-10 Compounds
GB1702221.1 2017-02-10
PCT/GB2018/050370 WO2018146486A1 (en) 2017-02-10 2018-02-09 Ampa receptor potentiators

Publications (2)

Publication Number Publication Date
RU2019126574A RU2019126574A (ru) 2021-03-10
RU2019126574A3 true RU2019126574A3 (ru) 2021-03-29

Family

ID=58462168

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019126574A RU2019126574A (ru) 2017-02-10 2018-02-09 Потенциаторы рецепторов ampa

Country Status (13)

Country Link
US (1) US11186567B2 (ru)
EP (1) EP3580213B1 (ru)
JP (1) JP7014808B2 (ru)
KR (1) KR102665887B1 (ru)
CN (1) CN110520418B (ru)
AU (1) AU2018218307C1 (ru)
CA (1) CA3051647A1 (ru)
ES (1) ES2974824T3 (ru)
GB (1) GB201702221D0 (ru)
MX (1) MX2019009537A (ru)
NZ (1) NZ755747A (ru)
RU (1) RU2019126574A (ru)
WO (1) WO2018146486A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds
WO2024255822A1 (zh) * 2023-06-15 2024-12-19 上海魁特迪生物科技有限公司 Dir结合剂及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW575561B (en) 1999-03-25 2004-02-11 Hoffmann La Roche 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
CN1245386C (zh) 2000-06-12 2006-03-15 卫材株式会社 1,2-二氢吡啶化合物及其制备方法和用途
WO2004046137A1 (en) 2002-11-21 2004-06-03 Vicore Pharma Ab New tricyclic angiotensin ii agonists
US8067418B2 (en) 2005-04-12 2011-11-29 Vicore Pharma Ab Tricyclic angiotensin II agonists
US7566735B2 (en) 2006-03-20 2009-07-28 Glaxo Group Limited Compounds which potentiate AMPA receptor and uses thereof in medicine
PL2049475T3 (pl) 2006-04-24 2012-08-31 Lilly Co Eli Pirolidynony podstawione cykloheksylem jako inhibitory 11-betahydrokysterydu dehydrogenazy 1
TW200817385A (en) * 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
EP2086643B1 (en) 2006-11-03 2011-03-23 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711088D0 (en) * 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0711089D0 (en) * 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
ATE554078T1 (de) 2007-07-26 2012-05-15 Vitae Pharmaceuticals Inc Synthese von 11-beta-hydroxysteroid-dehydrogenase-1-hemmern
EP2195303A4 (en) 2007-09-20 2011-07-20 Cortex Pharma Inc 3-SUBSTITUTED 1,2,3-TRIAZIN-4-ONE AND 3-SUBSTITUTED 1,3-PYRIMIDIONE FOR INCREASING GLUTAMATERGIC SYNAPTIC REACTIONS
GB0721094D0 (en) 2007-10-26 2007-12-05 Glaxo Group Ltd Compounds
TW200934497A (en) 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
WO2009134392A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW201012803A (en) * 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
TW201031649A (en) 2008-12-02 2010-09-01 Organon Nv 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives
PL2445883T3 (pl) 2009-06-26 2014-12-31 Pfizer Heterocykliczne sulfonamidy, ich zastosowania i kompozycje farmaceutyczne
WO2011132051A2 (en) 2010-04-19 2011-10-27 Glenmark Pharmaceuticals S.A. Tricycle compounds as phosphodiesterase-10 inhibitors
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds

Also Published As

Publication number Publication date
AU2018218307A1 (en) 2019-08-15
CA3051647A1 (en) 2018-08-16
AU2018218307B2 (en) 2022-02-24
JP2020507592A (ja) 2020-03-12
MX2019009537A (es) 2019-10-04
GB201702221D0 (en) 2017-03-29
EP3580213C0 (en) 2024-03-27
CN110520418A (zh) 2019-11-29
WO2018146486A1 (en) 2018-08-16
KR20190117549A (ko) 2019-10-16
NZ755747A (en) 2022-02-25
US11186567B2 (en) 2021-11-30
RU2019126574A (ru) 2021-03-10
BR112019016603A2 (pt) 2020-03-31
AU2018218307C1 (en) 2022-06-23
KR102665887B1 (ko) 2024-05-10
EP3580213A1 (en) 2019-12-18
ES2974824T3 (es) 2024-07-01
CN110520418B (zh) 2022-08-16
JP7014808B2 (ja) 2022-02-01
EP3580213B1 (en) 2024-03-27
US20210139463A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
BR122021024397A2 (ru)
BR122021000189A2 (ru)
BR112020006084A8 (ru)
BR112019008823A2 (ru)
RU2019126574A3 (ru)
BR202018014992U2 (ru)
BR122021023687A2 (ru)
BR122021014832A2 (ru)
BR112020008820A2 (ru)
BR202017025154U2 (ru)
BR102017023327A2 (ru)
BR202017021228U2 (ru)
BR202017020981U2 (ru)
BE2017C035I2 (ru)
BR102017015495A2 (ru)
BR102017015250A2 (ru)
BR102017014430A2 (ru)
BR102017003115A2 (ru)
CN303949240S9 (ru)
CN303892650S8 (ru)
CN304004763S (ru)
CN304003977S (ru)
CN304003468S (ru)
CN304009198S (ru)
CN304011301S (ru)

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant